Physician profile
Michael S Kendrick
NPI 1225098163
$89,713.17
in general payments reported to CMS, 2019-2025
60 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,599 · 2021: $4,474 · 2022: $5,084 · 2023: $10K · 2024: $44K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $31K · Food and Beverage: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $4,883 · Consulting Fee: $500 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $31,300.00 |
| Food and Beverage | $14,558.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,250.00 |
| Travel and Lodging | $4,883.21 |
| Consulting Fee | $500.00 |
| Education | $163.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $31,300.00 | 2024 | |
| Medtronic, INC. | $21,224.14 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Accurian |
| Boston Scientific Corporation | $16,523.22 | 2019-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, Infinion 16 |
| Vertos Medical, INC. | $3,650.82 | 2019-2024 | Mild Device Kit |
| Mml US, INC. | $2,682.50 | 2023-2025 | Reactiv8 |
| Spinal Simplicity, LLC | $2,347.12 | 2021-2025 | Ha Minuteman G3-R |
| Saluda Medical Americas, INC. | $2,303.87 | 2023-2025 | Evoke, Evoke Scs |
| Vertiflex, INC. | $1,783.01 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $969.68 | 2022-2024 | Siliq, Targretin, Duobrii |
| Forte Bio-Pharma LLC | $818.96 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Scilex Pharmaceuticals INC. | $574.26 | 2019-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $499.06 | 2019-2025 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $446.34 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Medtronic USA, INC. | $356.08 | 2019 | |
| Foundation Fusion Solutions, LLC | $302.75 | 2022-2023 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $242.16 | 2019-2022 | |
| Bausch Health US, LLC | $232.72 | 2022-2025 | Aplenzin |
| Biodelivery Sciences International, INC. | $211.69 | 2019-2021 | |
| Assertio Therapeutics, INC. | $196.62 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $195.24 | 2019-2022 | |
| Almatica Pharma LLC | $190.49 | 2021-2023 | Gralise |
| Redhill Biopharma INC. | $189.42 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $163.37 | 2022-2025 | Soliris, Ultomiris |
| Hikma Pharmaceuticals USA | $132.75 | 2021-2024 | Kloxxado |
| Daiichi Sankyo INC. | $131.54 | 2019 | |
| Mdd US Operations, LLC | $123.48 | 2019 | |
| Ibsa Pharma INC. | $120.70 | 2021-2024 | Tirosint, Tirosint, Licart |
| Relievant Medsystems, INC. | $117.67 | 2022 | |
| Abbott Laboratories | $112.23 | 2021-2025 | Proclaim |
| Amgen INC. | $107.85 | 2019-2021 | |
| Spr Therapeutics, INC | $104.96 | 2024-2025 | Sprint Pns System |
| Lilly USA, LLC | $98.87 | 2019 | |
| Nevro Corp. | $97.36 | 2022-2023 | Senza |
| Eisai INC. | $94.81 | 2020-2021 | |
| Si-Bone, INC. | $94.13 | 2020-2025 | |
| Axonics, INC. | $91.37 | 2024 | Axonics |
| Novartis Pharmaceuticals Corporation | $82.00 | 2019 | |
| Curonix LLC | $79.80 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nuvasive, INC. | $79.79 | 2019 | |
| Azurity Pharmaceuticals, INC. | $78.86 | 2023-2024 | Horizant, Horizant |
| Grt US Holding, INC. | $73.36 | 2021-2022 | |
| Globus Medical, INC. | $53.44 | 2025 | Senza |
| Horizon Therapeutics Plc | $50.93 | 2019-2021 | |
| Radius Health, INC. | $47.95 | 2022 | |
| Upsher-Smith Laboratories LLC | $39.38 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $36.45 | 2024 | Zilretta, Iovera |
| Pfizer INC. | $35.64 | 2019 | |
| Merck Sharp & Dohme LLC | $30.92 | 2022 | |
| Zyla Life Sciences, INC. | $27.74 | 2019-2020 | |
| Shionogi INC | $23.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.85 | 2019 | |
| Averitas Pharma INC. | $16.81 | 2025 | Qutenza |
| Trevena, INC. | $16.46 | 2023 | Olinvyk |
| Spinesmith Holdings, LLC | $14.78 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.79 | 2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $13.38 | 2020 | |
| Abbvie INC. | $12.50 | 2022 | |
| Neuronetics, INC. | $12.44 | 2022 | |
| Pernix Therapeutics Holdings, INC. | $11.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.